A- A A+

Controlling for pleasure and risk: The experiences of sexuality and gender diverse people who use GHB. 

Freestone J, Prestage G, Bourne A, Ezard N, Race K, Nedanoski A, Murray J, Siefried KJ. 

Int J Drug Policy. 2022 Jul;105:103747. doi: 10.1016/j.drugpo.2022.103747. Epub 2022 May 25. PMID: 35643047.

https://www.sciencedirect.com/science/article/pii/S0955395922001669

Ketamin: Antidepressiver Wirkmechanismus entdeckt

München – Der antidepressive Effekt von Ketamin könnte durch die Hochregulation bestimmter Kaliumkanäle im Hippocampus entstehen – den sogenannten KCNQ2. Zu diesem Ergebnis kam ein Forschungsteam des Max-Planck-Instituts für Psychiatrie (MPIP) in München, des Weizmann Institute of Science in Israel und des Helmholtz-Zentrums München anhand eines Mausmodells. (aerzteblatt.de, 01.06.2022)

https://www.aerzteblatt.de/nachrichten/134748/Ketamin-Antidepressiver-Wirkmechanismus-entdeckt

Drugs of abuse in tap water from eight European countries: Determination by use of supramolecular solvents and tentative evaluation of risks to human health. 

Muñiz-Bustamante L, Caballero-Casero N, Rubio S. 

Environ Int. 2022 Jun;164:107281. doi: 10.1016/j.envint.2022.107281. Epub 2022 May 6. PMID: 35561596.

https://www.sciencedirect.com/science/article/pii/S0160412022002082

Health Effects Associated With Kratom (Mitragyna speciosa) and Polysubstance Use: A Narrative Review. 

Striley CW, Hoeflich CC, Viegas AT, Berkowitz LA, Matthews EG, Akin LP, Iheanyi-Okeahialam C, Mansoor U, McCurdy CR. 

Subst Abuse. 2022 May 20;16:11782218221095873. doi: 10.1177/11782218221095873. PMID: 35645563; PMCID: PMC9130800.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9130800/

A Focus on Abuse/Misuse and Withdrawal Issues with Selective Serotonin Reuptake Inhibitors (SSRIs): Analysis of Both the European EMA and the US FAERS Pharmacovigilance Databases. 

Chiappini S, Vickers-Smith R, Guirguis A, Corkery JM, Martinotti G, Schifano F. 

Pharmaceuticals (Basel). 2022 May 1;15(5):565. doi: 10.3390/ph15050565. PMID: 35631391; PMCID: PMC9146999.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9146999/

UK/Frankreich. First the UK, now France: is needle-spiking spreading in European clubs?

Fear of needle-spiking is growing among clubbers in France, a few months after a wave of similar anxiety swept the UK. 

There have been more than 100 reports of needle-spiking in French clubs and bars since summer 2021. 

Needle-spiking involves the victim being injected against their will. Much like drink spiking, there have been reports of people being injected with Rohypnol or Gamma Hydroxybutyrate (GHB) – both known to be used as date-rape drugs. (euronews.culture, Frankreich, 13.05.2022)

https://www.euronews.com/culture/2022/05/12/first-the-uk-now-france-is-needle-spiking-spreading-in-european-clubs

Niederlande. First report of needle spiking now also in the Netherlands

Since last winter, there are reports of women being drugged on nights out in the UK, France and Belgium. Now, the first case has also surfaced in the Netherlands. (DutchReview, Niederlande, 11.05.2022)

https://dutchreview.com/news/first-report-of-needle-spiking-now-also-in-the-netherlands/

First Ever Clinical Trial with Ibogaine for Opioid Dependency

It’s been fifty years since the anti-addictive properties of ibogaine were discovered and finally the dream of those helping people with substance use disorder is coming true – clinical research that will set the stage for policy change and legal access. (ICEERS - International Center for Ethnobotanical Education, Research, and Service, Spanien, 14.04.2022)

https://www.iceers.org/first-ever-clinical-trial-with-ibogaine-for-opioid-dependency/

Eine ambulante Entzugsbehandlung von Kratom bei sozialer Phobie: psychotherapeutische Praxis trifft suchtpsychiatrische Institutsambulanz [An Outpatient Withdrawal Treatment of Kratom in Social Phobia: Psychotherapeutic Surgery Meets Addiction Psychiatric Outpatient Clinic]. 

Schmid P, Leibfarth M, Uhlmann C. 

Psychiatr Prax. 2022 May;49(4):217-220. German. doi: 10.1055/a-1787-4122. Epub 2022 May 6. PMID: 35523199.

Abstract

https://www.thieme-connect.de/products/ejournals/abstract/10.1055/a-1787-4122

Emergent Synthetic Stimulant Replacing Drug Sold as Ecstasy, Molly

In 2020 and 2021, the Schedule I drug eutylone—typically sold as ecstasy, Molly or MDMA—was the most commonly encountered synthetic stimulant in forensic casework. While regulated in countries beside the U.S., including Canada, the UK, Sweden and Germany, eutylone is not controlled under the 1961, 1971 or 1988 United Nations Conventions. (Forensic, USA, 02.05.2022)

https://www.forensicmag.com/585696-Emergent-Synthetic-Stimulant-Replacing-Drug-Sold-as-Ecstasy-Molly/

Associations between classic psychedelics and opioid use disorder in a nationally-representative U.S. adult sample. 

Jones, G., Ricard, J.A., Lipson, J. et al.

Sci Rep 12, 4099 (2022). doi.org/10.1038/s41598-022-08085-4

https://www.nature.com/articles/s41598-022-08085-4

LSD zum Frühstück

Weltweit nehmen immer mehr Menschen winzige Mengen an LSD zu sich, bevor sie sich auf den Weg zur Arbeit machen. Kreativer, konzentrierter, glücklicher – so lautet das Versprechen des »Microdosing«. Was ist dran an der Behauptung? (Spektrum, 26.01.2022)

https://www.spektrum.de/news/drogen-wie-gut-funktioniert-microdosing/1695152

Insights on the Impact of Gamma-Hydroxybutyrate (GHB) Abuse. 

Tay E, Lo WKW, Murnion B. Current 

Subst Abuse Rehabil. 2022 Feb 9;13:13-23. doi: 10.2147/SAR.S315720. PMID: 35173515; PMCID: PMC8843350.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8843350/

Khat, a Cultural Chewing Drug: A Toxicokinetic and Toxicodynamic Summary. 

Silva B, Soares J, Rocha-Pereira C, Mladěnka P, Remião F, On Behalf Of The Oemonom Researchers. 

Toxins (Basel). 2022 Jan 20;14(2):71. doi: 10.3390/toxins14020071. PMID: 35202099; PMCID: PMC8875844.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875844/

A review on the forensic toxicology of global drug-facilitated sexual assaults. 

Skov K, Johansen SS, Linnet K, Nielsen MKK. 

Eur Rev Med Pharmacol Sci. 2022 Jan;26(1):183-197. doi: 10.26355/eurrev_202201_27767. PMID: 35048994.

https://www.europeanreview.org/article/27767

Sierra Leone. Kush: Sierra Leone's new illegal drug (Video)

The BBC has heard reports of young people killing themselves or harming themselves and others. 

Medical staff in the capital Freetown say that 90% of the male admissions to the central psychiatric ward are due to Kush use. (BBC, UK, 07.02.2022, Video, 09:54)

https://www.bbc.com/news/av/world-africa-60260738

A systematic literature review of clinical trials and therapeutic applications of ibogaine. 

Köck P, Frölich K, Walter M, Lang U, Dürsteler KM. 

J Subst Abuse Treat. 2021 Dec 30:108717. doi: 10.1016/j.jsat.2021.108717. Epub ahead of print. PMID: 35012793.

https://linkinghub.elsevier.com/retrieve/pii/S0740-5472(21)00443-8

Adjunctive Ketamine With Relapse Prevention-Based Psychological Therapy in the Treatment of Alcohol Use Disorder. 

Grabski M, McAndrew A, Lawn W, Marsh B, Raymen L, Stevens T, Hardy L, Warren F, Bloomfield M, Borissova A, Maschauer E, Broomby R, Price R, Coathup R, Gilhooly D, Palmer E, Gordon-Williams R, Hill R, Harris J, Mollaahmetoglu OM, Curran HV, Brandner B, Lingford-Hughes A, Morgan CJA. 

Am J Psychiatry. 2022 Jan 11:appiajp202121030277. doi: 10.1176/appi.ajp.2021.21030277. Epub ahead of print. PMID: 35012326.

https://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.2021.21030277

Ketamin hilft Alkoholikern bei der Abstinenz

Exeter/England – Das Anästhetikum Ketamin kann in niedrigen Dosierungen auch zur Behandlung von psychiatrischen Erkrankungen eingesetzt werden. Nachdem das Enantiomer Esketamin als Nasenspray bereits zur Behandlung therapieresistenter Depressionen zugelassen ist, zeigt eine kürzlich im American Journal of Psychiatry (2021; DOI: 10.1176/appi.ajp.2021.21030277) publizierte Studie, dass Infusionen von Ketamin eine Psychotherapie unterstützen können. (aerzteblatt.de, 26.01.2022)

https://www.aerzteblatt.de/nachrichten/130809/Ketamin-hilft-Alkoholikern-bei-der-Abstinenz

Psilocybin targets a common molecular mechanism for cognitive impairment and increased craving in alcoholism. 

Meinhardt MW, Pfarr S, Fouquet G, Rohleder C, Meinhardt ML, Barroso-Flores J, Hoffmann R, Jeanblanc J, Paul E, Wagner K, Hansson AC, Köhr G, Meier N, von Bohlen Und Halbach O, Bell RL, Endepols H, Neumaier B, Schönig K, Bartsch D, Naassila M, Spanagel R, Sommer WH. Sci Adv. 2021 Nov 19;7(47):eabh2399. doi: 10.1126/sciadv.abh2399. Epub 2021 Nov 17. PMID: 34788104; PMCID: PMC8598005.

https://www.science.org/doi/10.1126/sciadv.abh2399

Wie die Droge Psilocybin Alkoholabhängigen zur Abstinenz verhelfen könnte

Mannheim – Das Pilzhalluzinogen Psilocybin, das in klinischen Studien bereits erfolgreich zur Behand­lung von Depressionen erprobt wurde, könnte Menschen mit einer Alkoholabhängigkeit helfen, ihre Sucht zu überwinden. Darauf deuten tierexperimentelle Studien in Science Advances (2021; DOI: 10.1126/sciadv.abh2399) hin. (aerzteblatt.de, 21.01.2022)

https://www.aerzteblatt.de/nachrichten/129335/Wie-die-Droge-Psilocybin-Alkoholabhaengigen-zur-Abstinenz-verhelfen-koennte

Ayahuasca Technical Report

26 pages with all the latest research-based facts about ayahuasca, its uses, pharmacology, legal status and therapeutic effects, signed by 11 world-class experts and researchers.

The 2021 Ayahuasca Technical Report and fact sheets synthesize the currently available research on ayahuasca and are a reliable source of information on what is (and what is not) known about ayahuasca. (ICEERS - International Center for Ethnobotanical Education, Research, and Service, Spanien, 21.12.2021)

https://www.iceers.org/ayahuasca-technical-report/

Ketamine for the treatment of mental health and substance use disorders: Comprehensive systematic review. 

Walsh, Z., Mollaahmetoglu, O., Rootman, J., Golsof, S., Keeler, J., Marsh, B., . . . Morgan, C. (2022). 

BJPsych Open, 8(1), E19. doi:10.1192/bjo.2021.1061

https://www.cambridge.org/core/journals/bjpsych-open/article/ketamine-for-the-treatment-of-mental-health-and-substance-use-disorders-comprehensive-systematic-review/36E261BFA62CDA6459B88F7777415FDA#.Ycn724EbuAw.twitter

Psilocybin study enrolls clinicians with COVID-linked blues

Enrollment has begun in a small study of whether psilocybin-assisted psychotherapy can help alleviate symptoms of depression and anxiety that front-line clinicians developed during the COVID-19 pandemic. (University of Washington School of Medicine, USA, 14.12.2021)

https://medicalxpress.com/news/2021-12-psilocybin-enrolls-clinicians-covid-linked-blues.html

Most Addiction Specialists Support Legalized Therapeutic Psychedelics

The majority of addiction specialists, including psychiatrists, believe psychedelics are promising for the treatment of substance use disorders (SUDs) and psychiatric illnesses and, with some caveats, support legalization of the substances for these indications, results of a new survey show. (MedScape, USA, 16.12.2021)

https://www.medscape.com/viewarticle/964987

Depressionen: Psychodroge Psilocybin in Phase-2-Studie wirksam

New York – Die einmalige Einnahme von Psilocybin, dem psychedelischen Inhaltsstoff bestimmter Pilzarten, hat in einer Phase-2-Studie therapieresistente Depressionen gelindert. Der Hersteller kündigte aufgrund der Ergebnisse eine Phase-3-Studie an, deren Ergebnisse in den USA zur Zulassung der streng verbotenen Droge als Arzneimittel führen könnte. Die FDA hat mit der Einstufung als mögliche „breakthrough therapy“ ein vereinfachtes Zulassungsverfahren zugesagt. (aerzteblatt.de, 13.12.2021)

https://www.aerzteblatt.de/nachrichten/129015/Depressionen-Psychodroge-Psilocybin-in-Phase-2-Studie-wirksam

Moving Past Mysticism in Psychedelic Science

James W. Sanders and Josjan Zijlmans

ACS Pharmacology & Translational Science 2021 4 (3), 1253-1255 

DOI: 10.1021/acsptsci.1c00097 

https://pubs.acs.org/doi/10.1021/acsptsci.1c00097

GLOBAL DRUG SURVEY (GDS) 2021 KEY FINDINGS REPORT

WINSTOCK AR, MAIER LJ, ZHUPARRIS A, DAVIES E, PULJEVIC C, KUYPERS KPC, FERRIS JA & BARRATT MJ. (2021). 

https://www.globaldrugsurvey.com/wp-content/uploads/2021/12/Report2021_global.pdf

Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder. 

Doss, M.K., Považan, M., Rosenberg, M.D. et al. 

Transl Psychiatry 11, 574 (2021). doi.org/10.1038/s41398-021-01706-y

https://rdcu.be/cBcpr

GDS2022: The 10th anniversary survey: Could you be participant 1 million?

Professor Adam Winstock, Dr Monica Barratt, Dr Emma Davies & Associate Professor Jason Ferris – GDS Core Research Team, on behalf of all at GDS 

Happy birthday to us! 2021 marks the 10th anniversary of the first ever Global Drug Survey. Since that time over 900,000 people have taken part in our surveys that have covered all aspects of drug use: everything from sex and drugs, drug delivery and darknet drug markets, changes in drug policy, vaping, novel drugs and the psychedelic renaissance. Throughout that diverse landscape we have kept our singular focus on promoting honest conversations about drug use and helping keep people safe regardless of the legal status of the drug. This year GDS2022 has chosen seven areas to focus on that we considered were of vital public health importance or piqued our curiosity. As always, all GDS surveys collect your data anonymously and confidentially. We have received ethics approval for this study from University College London. (GDS – Global Drug Survey, UK, November 2022)

https://www.globaldrugsurvey.com/contact/